RAMSAY HEALTH CARE LIMITED (RHC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RHC

RHC - RAMSAY HEALTH CARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.42
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Founded in Sydney in 1964, Ramsay Health Care is the largest provider of private healthcare in Australia, with operations in the UK, France, Indonesia and Malaysia. The company specialises in surgery, rehabilitation and psychiatric care. It was first listed in 1997.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$34.29

02 May
2025

0.610

OPEN

$33.51

1.81%

HIGH

$34.29

349,452

LOW

$33.42

TARGET
$38.158

-1.51 change from previous day

 11.3% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
RHC: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 381.6 121.8 xxx
DPS (cps) xxx 80.0 71.4 xxx
EPS Growth xxx 100.0% - 68.1% xxx
DPS Growth xxx 6.7% - 10.7% xxx
PE Ratio xxx N/A 28.7 xxx
Dividend Yield xxx N/A 2.0% xxx
Div Pay Ratio(%) xxx 21.0% 58.6% xxx

Dividend yield today if purchased 3 years ago: 1.02%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.29

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 11/03 - ex-div 40c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx381.6
DPS All xxxxxxxxxxxxxxx80.0
Sales/Revenue xxxxxxxxxxxxxxx16,665.4 M
Book Value Per Share xxxxxxxxxxxxxxx2,030.3
Net Operating Cash Flow xxxxxxxxxxxxxxx1,302.0 M
Net Profit Margin xxxxxxxxxxxxxxx1.62 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx5.94 %
Return on Invested Capital xxxxxxxxxxxxxxx1.76 %
Return on Assets xxxxxxxxxxxxxxx1.27 %
Return on Equity xxxxxxxxxxxxxxx5.98 %
Return on Total Capital xxxxxxxxxxxxxxx5.65 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx413.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx606 M
Long Term Debt xxxxxxxxxxxxxxx10,332 M
Total Debt xxxxxxxxxxxxxxx10,938 M
Goodwill - Gross xxxxxxxxxxxxxxx5,745 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx662 M
Price To Book Value xxxxxxxxxxxxxxx2.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx753.8 M
Capex % of Sales xxxxxxxxxxxxxxx4.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx15,055 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx674 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx112 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

28/02/2025

3

Hold

$37.10

8.19%

Ramsay Health Care reported 1H25 EBIT of $500m, in line with guidance, driven by low single-digit admissions growth and indexation gains, Morgans notes.

The broker details mixed performance, with growth in Australian and UK acute hospitals offset by declines in Elysium and the EU due to inflationary pressures.

Management is reviewing strategic options for the EU division, with a potential divestment under consideration.

Operating cash flow rose 44%, while return on capital employed improved by -100bps. The fully franked dividend remains flat at 40c. FY25 guidance was qualitative, indicating slower activity growth.

Morgans lowers FY25-27 NPAT forecasts by -6%/-4%/-3%, respectively, on lower operating margins and higher tax. Target price slips to $37.10 from $37.74. Hold rating unchanged.

FORECAST
Morgans forecasts a full year FY25 dividend of 80.00 cents and EPS of 128.00 cents.
Morgans forecasts a full year FY26 dividend of 104.00 cents and EPS of 164.00 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

3

xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

06/03/2025

3

Neutral

$44.44

29.60%

Jarden was "relieved" with the first half result from Ramsay Health Care with EBIT only slightly missing estimates.

Ramsay Sante has been named as the focus of a strategic review and, if divestment is possible, this should represent a significant catalyst, the broker assesses.

Jarden retains a Neutral rating and reduces the target to $44.44 from $48.22.

FORECAST
Jarden forecasts a full year FY25 dividend of 75.80 cents and EPS of 124.80 cents.
Jarden forecasts a full year FY26 dividend of 87.00 cents and EPS of 143.40 cents.
Access Extra Coverage Research History >

RHC STOCK CHART

FNArena News on RHC

1
Rudi’s View: Mag7 Dominance & Profit Warnings

May 01 2025 - Rudi's View
2
Rudi’s View: Awaiting The Real World Ramifications

Apr 30 2025 - Rudi's View
3
In Brief: Tariffs, Healthcare & Wealth Platforms

Apr 11 2025 - Weekly Reports
4
Rudi’s View: Best Buys & Conviction Calls On ASX

Apr 10 2025 - Rudi's View
5
Rudi’s View: Share Market Scenarios & Dilemmas

Apr 09 2025 - Rudi's View

Latest Healthcare services News

1
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
2
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
3
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
4
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
5
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
6
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
7
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
8
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
9
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
10
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps